The use of famotidine in the treatment of Parkinson's disease: a pilot study.
Seven patients with idiopathic Parkinson's disease were enrolled in a ten week study to evaluate the efficacy of famotidine, an histamine H2-antagonist, in the treatment of bradyphrenia. Patients received famotidine 80 mg/day for a period of six weeks and were evaluated with neuropsychological tests. Overall, patients demonstrated improvement in variables measured. Some patients also reported an improvement in their motor symptoms.
Department of Neurology, Mount Sinai Medical Center, New York, NY, USA.
S P
SP
Molinari
R
R
Kaminski
A
A
Di Rocco
M D
MD
Yahr
D000368:Aged; D003071:Cognition / Q000502:physiology; D015738:Famotidine / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D010865:Pilot Projects; D011597:Psychomotor Performance / Q000502:physiology
D006635:Histamine H2 Antagonists; D015738:Famotidine